Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway

International Immunopharmacology

Volumn 3, Issue 1, 2003, Pages 63-73

  D'Agostino, Pietro ^a   Ferlazzo, Viviana ^a   Milano, Salvatore ^a   La Rosa, Marzia ^b   Di Bella, Gloria ^b   Caruso, Rosalba ^b   Barbera, Caterina ^b   Grimaudo, Stefania ^a   Tolomeo, Manlio ^a   Feo, Salvatore ^a   Cillari, Enrico ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Apoptosis; Bcl 2; c myc; Caspases; Chemically modified tetracyclines

Indexed keywords

ACRIDINE ORANGE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLGLUTAMYLASPARTYLTHREONYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 8; CASPASE 9; ENZYME INHIBITOR; ETHIDIUM BROMIDE; KETONE DERIVATIVE; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL 2; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CYCLE; CELL LINE; CELL STRUCTURE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; MACROPHAGE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; REGULATORY MECHANISM; TUMOR CELL;

ANIMALS; APOPTOSIS; CASPASES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MACROPHAGES, PERITONEAL; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TETRACYCLINE; TETRACYCLINES; TUMOR CELLS, CULTURED;

EID: 0037244608     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00213-8     Document Type: Article

References (39)

1. Golub L.M., Suomalainem K., Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr. Opin. Dent. 2:1992;80-90.
2. Cillari E., Milano S., D'Agostino P.et al. Modulation of nitric oxide production by tetracyclines and chemically modified tetracyclines. Adv. Dent. Res. 12:1998;126-130.
3. D'Agostino P., Ferlazzo V., Milano S.et al. Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int. Immunopharmacol. 1:2001;1765-1776.
4. D'Agostino P., La Rosa M., Barbera C.et al. Doxycycline reduces mortality to lethal endotoxemia by reducing nitric oxide synthesis via an interleukin-10-independent mechanism. J. Infect. Dis. 177:1998;489-492.
5. Milano S., Arcoleo F., D'Agostino P., Cillari E. Intraperitoneal injection of tetracyclines protect mice from lethal endotoxemia down-regulating inducible nitric oxide synthase in various organs and cytokines and nitrate secretion in the blood. Antimicrob. Agents Chemother. 41:1997;117-121.
6. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:1993;2002-2012.
7. Kröncke K.D., Fehsel K., Kolb-Bachofen V. Nitric oxide: cytotoxicity versus cytoprotection - how, why, when and where? Nitric Oxide. 2:1997;107-120.
8. Albina J.E., Cui S., Mateo R.B., Reichner J.S. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J. Immunol. 150:1993;5080-5085.
9. Kolb H., Kolb-Bachofen V. Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? Immunol. Today. 19:1998;556-561.
10. Kröncke K.D., Brenner H.H., Rodriguez M.L.et al. Pancreatic islet cells are highly susceptible towards the cytotoxic effects of chemically generated nitric oxide. Biochim. Biophys. Acta. 182:1993;221-229.
11. Mitrovic B., Ignaro L.J., Vinters H.V.et al. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience. 2:1995;531-539.
12. Steller H. Mechanisms and genes of cellular suicide. Science. 267:1995;1445-1449.
13. Stennicke H.R., Salvesen G.S. Biochemical characteristic of caspase-3, -6, -7, and -8. J. Biol. Chem. 272:1997;25719-25723.
14. Vaux D.L. Immunopathology of apoptosis - introduction and overview. Springer Semin. Immunopathol. 19:1998;271.
15. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated Dnase that degrades DNA during apoptosis and its inhibitor ICAD. Nature. 391:1998;43-50.
16. Nicholson D.W., Thornberry N.A. Caspases: killer proteases. TIBS. 22:1997;299-306.
17. Douglas R.G., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
18. Yang E., Korsmeyer S.J. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood. 88:1996;386-401.
19. Boise L.H., Thompson C.B. Bcl-xL can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3759-3764.
20. Gibson L., Holmgreen S.P., Huang D.C.S.et al. bcl-w, a novel member of the bcl-2 family, promotes survival. Oncogene. 13:1996;665-675.
21. Kiefer M.C., Brauer M.J., Powers V.C.et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature. 374:1995;736-739.
22. Oltavai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
23. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax, and promotes cell death. Cell. 80:1995;285-291.
24. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
25. Alitalo K., Schwab M., Lin C.C., Varmus H.E., Bishop J.M. Homogeneously staining chromosomal regions contain amplified copie: an abundantly expressed cellular oncogene (c-myc) in malignant neuro-endocrine cells from a human colon carcinoma. Proc. Natl. Acad. Sci. U. S. A. 80:1993;1707-1711.
26. Hueber A.O., Zorning M., Lyon D., Suda T., Nagata S., Evan G. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309.
27. Evan G., Harrington E., Fanidi A., Land H., Amati B., Bennett M. Integrated control of cell proliferation and cell death by the c-myc oncogene. Philos. Trans. R. Soc. Lond., B Biol. Sci. 345:1994;269-275.
28. Fife R.S., Rougraff B.T., Proctor C., Sledge G.W. Jr. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J. Lab. Clin. Med. 130:1997;530-534.
29. Fife R.S., Sledge G.W. Jr. Effects of doxycycline on cancer cells in vitro and in vivo. Adv. Dent. Res. 12:1998;94-96.
30. Tolomeo M., Grimaudo S., Milano S.et al. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant, and apoptosis resistant leukemia cell lines. Br. J. Pharmacol. 133:2001;306-314.
31. Ekert P.G., Silke J., Vaux D.L. Caspase inhibitors. Cell Death Differ. 6:1999;1081-1086.
32. Lokeshwar B.L., Escatel E., Zhu B. Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline (CMT-3) (COL-3). Curr. Med. Chem. 3:2001;271-279.
33. Nelson M.L. Chemical and biological dynamics of tetracyclines. Adv. Dent. Res. 12:1998;5-11.
34. Pan G., O'Rourke K., Dixit V.M. Caspase-9, Bcl-xL, and Apaf-1 form a ternary complex. J. Biol. Chem. 273:1998;5841-5845.
35. Thornberry N.A., Rano T.A., Peterson E.P.et al. A combinatorial approach defines specificities of members of the caspase family and granzyme: B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272:1997;17907-17911.
36. Shinoura N., Yoshida Y., Nishimura M.et al. Expression level of Bcl-2 determines anti- or proapoptotic function. Cancer Res. 59:1999;4119-4128.
37. Ramamurthy N.S., McClain S.A., Pirila E.et al. Wound healing in aged normal and ovariectomized rats: effects of chemically modified doxycycline (CMT-8) on MMP expression and collagen synthesis. Ann. N.Y. Acad. Sci. 878:1999;720-723.
38. Lokeshwar B.L., Houston-Clark H.L., Selzer M.G., Block N.L., Golub L.M. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer. Adv. Dent. Res. 12:1998;97-102.
39. Selzer M.G., Zhu B., Block N.L., Lokeshwar B.L. CMT-3, a chemically modified tetracycline, inhibits born metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann. N.Y. Acad. Sci. 878:1999;678-682.